FDA authorizes Vir-GSK antibody as variants threaten Eli Lilly mAb

FDA authorizes Vir-GSK antibody as variants threaten Eli Lilly mAb

Source: 
Endpoints
snippet: 

The FDA has authorized the Covid-19 monoclonal antibody treatment from Vir and GlaxoSmithKline, adding another potent treatment option as the pandemic continues to rage in many corners of the world and as new variants threaten to render one of two rival approaches obsolete.